Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan Methyl Ester SCHEMBL122907 | 1.00 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL1195735 | 1.00 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL30180690 | 1.00 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL19161138 | 1.00 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL475266 | 0.99 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL29401004 | 0.99 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL29398306 | 0.99 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL378072 | 0.99 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL378071 | 0.99 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL28130766 | 0.99 | KDM4E (0.72) | MEN1KMT2AKDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569745-A | Spiroindole alkaloid in Polygonum tinctorium, and preparation method and application thereof | 沈阳药科大学 | 2025-03-07 | — | — | CN | claimed |
| CN-115728428-B | Determination method of tadalafil intermediate cis-tetrahydrocarboline hydrochloride related substances | 山东省医药工业设计院有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-114839308-B | Method for detecting L-tryptophan methyl ester hydrochloride in D-tryptophan methyl ester hydrochloride | 江苏天士力帝益药业有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118666841-A | Indole-tetramic acid compound, preparation and medical application thereof | 中国医学科学院药物研究所 | 2024-09-20 | — | — | CN | claimed |
| CN-117843636-A | Tadalafil intermediate and synthesis method of Tadalafil | 平光制药股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117843638-A | Preparation and application of bifunctional molecular compound based on RSL3 induced GPX4 protein degradation | 沈阳药科大学 | 2024-04-09 | — | — | CN | claimed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| CN-114805345-B | Preparation method of tadalafil intermediate cis-tetrahydrocarboline hydrochloride | 山东省药学科学院 | 2023-11-10 | — | — | CN | claimed |
| CN-116574102-A | Preparation method of tadalafil | 广东九明制药有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-1812435-A2 | PREPARATION OF TADALAFIL INTERMEDIATES | Teva Pharmaceutical Industries Ltd (IL) | 2007-08-01 | — | — | EP | claimed |
| US-7223863-B2 | Process for preparing Tadalafil and its intermediate | ALEMBIC LIMITED (IN) | 2007-05-29 | — | — | US | claimed |
| WO-2007052283-A1 | AN IMPROVED PROCESS FOR PREPARING TADALAFIL AND ITS INTERMEDIATE | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | claimed |
| US-20060276652-A1 | Preparation of tadalafil intermediates | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060258865-A1 | Process for preparing Tadalafil and its intermediate | ALEMBIC LIMITED (IN) | 2006-11-16 | — | — | US | claimed |
| WO-2006110893-A2 | PREPARATION OF TADALAFIL INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-10-19 | — | — | WO | claimed |
| US-20060004203-A1 | Modified pictet-spengler reaction and products prepared therefrom | ICOS CORPORATION | 2006-01-05 | — | — | US | claimed |
| CN-1671706-A | Modified pictet-spengler reaction and products prepared therefrom | LILLY ICOS LLC (US) | 2005-09-21 | — | — | CN | claimed |
| EP-1546149-A1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | Lilly Icos LLC (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004011463-A1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | LILLY ICOS, LLC. (US) | 2004-02-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004203-A1 | Modified pictet-spengler reaction and products prepared therefrom | WEE2, WEE1, WASF2 | MEN1 524/4885KMT2A 1536/4885KDM4E 3331/4885 |
| US-20060276652-A1 | Preparation of tadalafil intermediates | PDE3A, PDE3B, PDE5A | MEN1 4341/4885KMT2A 3376/4885KDM4E 2776/4885 |
| US-20060258865-A1 | Process for preparing Tadalafil and its intermediate | PDE3B, PDE5A, PDE3A | MEN1 3113/4885KMT2A 2896/4885KDM4E 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.